Levy Health Aims to Speed Up Fertility Diagnoses with AI Support
Image: Levy Health
Fertility health has long been a difficult journey for women, who have often had to go through years of uncertainty before reaching a diagnosis. Levy Health, a San Francisco-based startup, aims to change that by offering faster and more accurate diagnoses of fertility problems. Co-founded by Caroline Mitterdorfer, who was inspired by her personal health issues, the company aims to address delays in fertility diagnoses through an AI-powered clinical decision support platform.
The platform allows patients to input vital information, such as their fertility history and lab results, which AI then analyzes to narrow down potential fertility issues from a list of 110 conditions. By automating this process, physicians receive key information before meeting with patients, helping to reduce diagnosis time by 50%.
Unlike traditional avenues, where women typically consult obstetrician-gynecologists, who may not be fertility specialists, Levy Health offers a more focused and efficient approach. After launching in 2022 in Germany, the company moved to the United States to tap into the burgeoning fertility market, which is estimated to grow from $6.19 billion in 2023 to $10.11 billion in 2033.
Backed by a recent $4.5 million seed round, they are poised to continue their mission to transform fertility care. The startup is already partnering with key companies such as Progyny and Boston IVF, and plans to publish clinical studies on fertility and egg freezing to further validate its solution.
With a growing market and innovative AI approach, Levy Health aims to empower both patients and healthcare providers, ensuring more women receive timely diagnoses and the care they need to make informed decisions about their fertility journey.
